Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement...

Wound Management Technologies, Inc. Announced Today That It Has Reached an
Agreement in Principal to Acquire BioPharma Management Technologies, Inc.

FORT WORTH, Texas, June 16 /PRNewswire/ -- Wound Care Innovations, LLC, a
subsidiary of Wound Management Technologies, Inc., (WNDM.OB), announced today
that it has reached an agreement in principle to acquire BioPharma Management
Technologies, Inc., a privately held biotechnology company with a platform of
proprietary and patented technologies for topical pain management and
resorbable orthoses. The transaction would be structured as a share exchange
pursuant to which BioPharma would become a wholly owned subsidiary of Wound
Management in exchange for 5,000,000 shares of Wound Management common stock.
The transaction is subject to certain contingencies, including a complete
legal, financial and technical review of BioPharma by Wound Management.

"We believe that BioPharma's proprietary technologies and its future products
will be complementary to CellerateRx and will provide a broad application
across several of the medical markets that we currently serve," said Mr. Scott
Haire, Wound Management's Chief Executive Officer. "We have been focused on
bringing the science and technology of CellerateRx to the market over the past
year, and we believe that the additional science and technology behind
BioPharma would solidify Wound Management as a leading provider of wound care
products."

About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its
corporate headquarters in Fort Worth, Texas, markets and distributes wound
care products to the healthcare market under patented technology licensed to
the Company. The Company is positioned and seeks to be a leading provider of
wound care products. For more information on the Company please visit the
Company's Website at www.Celleraterx.com .

About BioPharma Management Technologies, Inc.:
BioPharma is a biotechnology company that recently launched the development
proprietary technologies and associated product applications for topical pain
management and resorbable orthoses.

"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of
1995: The statements in the press release that relate to the company's
expectations with regard to the future impact on the company's results from
new products in development are "forward-looking statements," within the
meaning of the Private Securities Litigation Reform Act of 1995. Since this
information may contain statements that involve risk and uncertainties and are
subject to change at any time, the company's actual results may differ
materially from expected results. This document may contain forward-looking
statements concerning the Company's operations, current and future performance
and financial condition. These items involve risks and uncertainties such as
product demand, market and customer acceptance, the effect of economic
conditions, competition, pricing, the ability to consummate and integrate
acquisitions, and other risks and uncertainties detailed in the Company's SEC
filings. The Company undertakes no obligation to revise any of these
statements to reflect the future circumstances or the occurrence of
unanticipated events.

For Further Information:
Product Information Shareholder Relations
Cathy Bradshaw Lucy Singleton
President Secretary
954-315-9242 817-820-7080

SOURCE Wound Management Technologies, Inc.

Product Information, Cathy Bradshaw, President, +1-954-315-9242, or
Shareholder Relations, Lucy Singleton, Secretary, +1-817-820-7080, both of
Wound Management Technologies, Inc.